{
    "clinical_study": {
        "@rank": "24886", 
        "arm_group": [
            {
                "arm_group_label": "Active AlphaCore device", 
                "arm_group_type": "Active Comparator", 
                "description": "AlphaCore active stimulation treatment"
            }, 
            {
                "arm_group_label": "Sham AlphaCore device", 
                "arm_group_type": "Sham Comparator", 
                "description": "AlphaCore sham device"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will assess the treatment of patients with Chronic Obstructive Pulmonary Disease\n      (COPD) stage III and IV who will self administer the AlphaCore stimulation three times a day\n      over a course of 2 months.  Patients will either receive an active AlphaCore device or a\n      Sham device during these two months while not knowing which device they have been provided.\n      At the end of the two months, all patients will be asked to continue in the study for\n      another 2 months to self administer with the active AlphaCore device.  Subjects will\n      complete diaries at home on their breathing and quality of life and will return to the\n      clinic monthly for assessment by the investigator."
        }, 
        "brief_title": "Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic Treatment", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "PERFORMANCE AND SAFETY VARIABLES:\n\n      The primary efficacy endpoint for this study is the total Chronic obstructive pulmonary\n      disease (COPD) Assessment Test (CAT) score change from baseline to the 8 week follow-up\n      period comparing the two device groups.\n\n      Secondary efficacy endpoints will be the mean difference from baseline to the 8 week\n      follow-up for the following assessments: Medical Research Council (MRC) dyspnoea scale, 6\n      minutes walking test and Forced Expiratory Volume in one second (FEV1)\n\n      Safety Variables:\n\n      Each subject will be assessed throughout the study for Adverse Events and at the last visit\n      (4 months) subjects will undergo another physical examination including vital signs and\n      blood pressure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 40-75 years\n\n          -  Diagnosed Chronic obstructive pulmonary disease(COPD) stage III and IV according to\n             Global Initiative for chronic obstructive lung disease (GOLD) guideline\n\n          -  Forced expiratory volume in one second (FEV 1) < 50%\n\n          -  Forced expiratory volume in one second (FEV1/Forced expiratory vital capacity (FVC) <\n             70%\n\n          -  Signed informed consent form\n\n        Exclusion Criteria:\n\n          -  Participation in other clinical trials (drug or medical device) 30 days prior to\n             start of this study\n\n          -  Subject is unable to comply with the procedures if the protocol for the study or any\n             other reason judged by the Investigator that could interfere with the study\n             assessment or follow-up\n\n          -  Has an abscess or other infection or lesion (including lymphadenopathy) at the\n             AlphaCore\u00ae treatment site.\n\n          -  Is currently implanted with an electrical and/or neurostimulator device, including\n             but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep\n             brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.\n\n          -  Has a history of carotid endarterectomy or vascular neck surgery on the right side.\n\n          -  Right side or bilateral vagotomy\n\n          -  Has a recent or repeated history of syncope.\n\n          -  Has a recent or repeated history of seizures.\n\n          -  Pregnant or breast feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679314", 
            "org_study_id": "AC-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Active AlphaCore device", 
                "Sham AlphaCore device"
            ], 
            "description": "Each study group will go under the same treatment regimen and assessments.", 
            "intervention_name": "AlphaCore device", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "vagus nerve stimulation", 
            "vagal nerve stimulation", 
            "nVNS", 
            "VNS", 
            "non invasive", 
            "gammacore"
        ], 
        "lastchanged_date": "October 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Schwedt", 
                    "country": "Germany", 
                    "state": "Oder", 
                    "zip": "D-16303"
                }, 
                "name": "Praxis fur Pneumologie am Asklepios Klinikum Uckermark"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Single Site, Randomized, Controlled, Parallel Group Study in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Stage III and IV Using AlphaCore or Sham (Control, Not Active) as a Prophylactic Treatment", 
        "overall_official": {
            "affiliation": "Praxis f\u00fcr Pneumologie am Asklepios Klinikum Uckermark", 
            "last_name": "Matthias John, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Chronic obstructive pulmonary disease Assessment Test (CAT) scores (Quality of life and symptoms) changes within a treatment period and comparison between the two groups", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679314"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Borg dyspnoea", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "6 minutes walking test", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "FEV1", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "EQ5D", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Throughout the course of the study (baseline to the 4 month follow-up visit)"
            }
        ], 
        "source": "ElectroCore LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ElectroCore LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}